Physician profile
Sunitha Menon
NPI 1487013645
$3,651.69
in general payments reported to CMS, 2019-2025
25 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $499 · 2022: $415 · 2023: $508 · 2024: $549 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,738.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $389.20 | 2024-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $362.05 | 2021-2025 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $358.00 | 2023-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $322.14 | 2021-2023 | S-Icd System Magnet |
| Abbott Laboratories | $258.88 | 2021-2025 | Cardiomems |
| Cvrx, INC. | $252.75 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.25 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $207.91 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $194.89 | 2024-2025 | Verquvo |
| Abiomed | $144.57 | 2025 | |
| Novo Nordisk INC | $142.08 | 2025 | Wegovy |
| Pfizer INC. | $120.98 | 2024-2025 | |
| Medtronic, INC. | $120.50 | 2023 | Venaseal |
| Esperion Therapeutics, INC. | $84.76 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $76.21 | 2024 | Arcalyst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $71.47 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $64.61 | 2024-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $61.56 | 2024-2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $48.12 | 2024 | Xarelto |
| Scpharmaceuticals INC. | $39.79 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $33.13 | 2025 | Opsumit |
| Shockwave Medical, INC | $26.92 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Regeneron Healthcare Solutions, INC. | $24.35 | 2025 | Evkeeza |
| Innovation Technologies INC | $15.04 | 2025 | Irrisept |
| Bridgebio Pharma, INC. | $14.53 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunitha Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.